安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Guselkumab - Wikipedia
Guselkumab ( ɡjuˈsɛlkjumæb gew-SEL-kew-mab; sold under the brand name Tremfya) is a human monoclonal antibody against interleukin-23 used for the treatment of plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease [5][6][7][8]
- Official Consumer Website for TREMFYA® (guselkumab)
Learn about treatment with TREMFYA® (guselkumab) across all uses, including the support program, TREMFYA withMe, on the official patient website See full Prescribing Safety Info
- Guselkumab: Uses, Dosage, Side Effects, Warnings - Drugs. com
Guselkumab (Tremfya) is an injectable medication used to treat inflammatory, autoimmune conditions plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis, in certain patients Guselkumab helps reduce inflammation, pain, swelling, and skin, joint and gastric symptoms
- Guselkumab (subcutaneous route) - Side effects dosage
Guselkumab injection is used to treat moderate to severe plaque psoriasis in patients who may benefit from receiving phototherapy (ultraviolet light treatment) or other treatments
- Tremfya (guselkumab): Uses, dosage, side effects, and precautions
Learn about Tremfya (guselkumab), including its uses for psoriasis and arthritis, typical dosage, common side effects, important safety precautions, plus cost info
- Tremfya (guselkumab) dosing, indications, interactions, adverse effects . . .
Medscape - Psoriasis dosing for Tremfya (guselkumab), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy lactation schedules, and cost information
- FDA approves label expansion, cementing TREMFYA
HORSHAM, PA – (May 28, 2026) – Johnson Johnson (NYSE: JNJ) announced today that the U S Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) to include evidence in the TREMFYA ® (guselkumab) label for the inhibition of progression of structural joint damage in adults with active psoriatic arthritis (PsA) The inclusion of this key outcome
- label - accessdata. fda. gov
Guselkumab, an interleukin-23 antagonist, is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody Guselkumab is produced in a mammalian cell line using recombinant DNA technology and
|
|
|